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The BEST study — a prospective study to compare 
business class versus economy class air travel as a cause 
of thrombosis
Barry F Jacobson, Marion Münster, Alberto Smith, Kevin G Burnand, Andrew Carter, A Talib O Abdool-Carrim, Elizabeth
Marcos, Piet J Becker, Timothy Rogers, Dirk le Roux, Jennifer LCalvert-Evers, Marietha J Nel, Robyn Brackin, Martin Veller
Background. As many as 10% of airline passengers travelling
without prophylaxis for long distances may develop a venous
thrombosis. There is, however, no evidence that economy
class travellers are at increased risk of thrombosis.
Objectives. A suitably powered prospective study, based on
the incidence of deep-vein thrombosis (DVT) reported in
previous studies on long-haul flights, was designed to
determine the incidence of positive venous duplex scans and
D-dimer elevations in low and intermediate-risk passengers,
comparing passengers travelling in business and economy
class.
Patients/methods. Eight hundred and ninety-nine passengers
were recruited (180 travelling business class and 719
travelling economy). D-dimers were measured before and
after the flight. A value greater than 500 ng/ml was accepted
as abnormal. A thrombophilia screen was conducted which
included the factor V Leiden mutation, the prothombin
20210Amutation, protein C and S levels, antithrombin levels,
and anticardiolipin antibodies immunoglobulin G (IgG) and
immunoglobulin M (IgM). On arrival, lower limb
compression ultrasonography of the deep veins was
performed. Logistical regression analysis was used to
determine the risk factors related to abnormally high D-dimer
levels.
Results. Only 434 subjects had a full venous duplex scan
performed. None had ultrasonic evidence of venous
thrombosis. Nine passengers tested at departure had elevated
D-dimer levels and these volunteers were excluded from
further study. Seventy-four of the 899 passengers had raised
D-dimers on arrival. Twenty-two of 180 business class
passengers (12%) developed elevated D-dimers compared
with 52 of 719 economy class passengers (7%). There was no
significant association between elevation of D-dimers and the
class flown (odds ratio (OR) 0.61, p = 0.109). The factor V
Leiden mutation, factor VIII levels and the use of aspirin
were, however, associated with raised D-dimers (OR 3.36, 
p = 0.024; OR 1.01, p = 0.014; and OR 2.04, p = 0.038,
respectively). Five hundred and five passengers were
contacted within 6 months and none reported any symptoms
of a clinical thrombosis or pulmonary embolus.
Conclusion. The incidence of ultrasonically proven DVT is
much lower than previously reported. However, more than
10% of all passengers developed raised D-dimers, which were
unrelated to the class flown. A rise in D-dimers is associated
with an inherent risk of thrombosis and/or thrombophilia,
demonstrates activation of both the coagulation and
fibrinolytic systems during long-haul flights, and may
indicate the development of small thrombi.
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The association between venous thromboembolism (VTE) and
air travel has received considerable attention because of several
recent media and scientific reports of fatal pulmonary emboli
developing in passengers, either during flights or shortly after
disembarking. Although not confined to flying, travel-
associated thrombosis is commonly referred to as the ‘economy
class syndrome’. The term evolved from the premise that the
underlying aetiology of VTE is venous stasis secondary to
relative immobility; a consequence of being confined to seating
with limited legroom. Flight-simulation studies have shown
that venous stasis is a consequence of being seated in an
aircraft for prolonged periods of time. 1 A number of studies
have provided evidence that there is a link between long-haul
air travel and VTE,2-6 although it is accepted that this risk has
not been adequately quantified.7 As yet, no study has
demonstrated that passengers travelling in economy class are
more predisposed to VTE than those travelling in business
class or first class, where there is more legroom and seats
recline.
The BEST study (Business class versus Economy class
Syndrome as a cause of Thrombosis) was designed to be the
first large prospective study to compare the incidence of VTE
in low- and intermediate-risk8 economy class and business
class passengers. All passengers with any identifiable
predisposition to VTE were excluded. The intention was to
determine the incidence of thrombosis using a strategy
combining D-dimer measurement on departure and arrival,
and a full evaluation of all the deep veins by compression
ultrasound of all participating passengers on arrival. The study
was also designed to evaluate factors such as fluid and alcohol
intake, exercise, smoking status and medication.
Although recent media reports have dramatised the
‘economy class syndrome’, a World Health Organisation
(WHO) report7 suggests that the actual incidence of travel-
associated VTE might be much lower than previously
estimated. In an attempt to quantify the true incidence
accurately we decided to use D-dimers as well as compression
ultrasonography (CUS). CUS is an excellent technique to assess
venous thrombosis above the knee. Unfortunately, the
sensitivity of this technique diminishes markedly below the
knee.9 The D-dimer, a specific degradation product of cross-
linked fibrin, is a well-established highly sensitive test for the
detection of VTE.10,11 We therefore decided to use positive D-
dimers (‡ 500 ng/ml) as an indicator to identify passengers
with travel-induced thrombotic activity.
As the risk of VTE is known to increase with duration of
travel,6 the London-to-Johannesburg route was chosen. It has a
flight duration of approximately 11 hours and is therefore a
‘high-risk’ flight, with the added advantage of not having
major time zone changes as a potential confounding variable.
Materials and methods
Recruitment
Passengers booked on two daily non-stop scheduled flights
from London’s Heathrow Airport to Johannesburg
International Airport, between April 2002 and June 2002, were
approached for inclusion in the study at the South African
Airways check-in desk. An estimate of the number of
passengers required to evaluate the increased risk of
thrombosis caused by long-haul flight was derived from two
other prospective studies3,5 which reported an incidence of
between 3% and 10%. The aim was to enrol approximately 
1 000 passengers, as this would give a greater than 90% power
to detect a lower incidence of thrombosis than that previously
reported. There was an active attempt to recruit equal numbers
of economy class and business class passengers. Financial
constraints limited the duration of the study, which was
terminated before equivalent numbers of business class
passengers could be recruited.
Exclusion criteria were a known history of VTE, current
warfarin and/or low-molecular-weight heparin usage,
pregnancy, surgery within the last 6 weeks and the intention to
use medical support stockings in-flight. All passengers who
agreed to participate were required to sign a consent form,
complete pre- and post-flight questionnaires, and undertake
pre- and post-flight blood sampling. Ultrasonography of the
lower limbs on disembarking was encouraged but optional. All
participants who completed the study were allotted an extra
5 000 South African Airways Voyager Air Miles (frequent flyer)
for the flight.
Questionnaire
A questionnaire documenting the class flown, age, gender,
height and weight, was given to passengers on departure. They
were asked to record their in-flight fluid intake (non-alcoholic
and alcoholic) and amount of in-flight exercise performed.
Smoking status, use of aspirin, anti-inflammatory agents,
sleeping tablets, oral contraceptives (OC) and hormone
replacement therapy (HRT) were also documented.
Phlebotomy
Ven e p u n t u re was performed after check-in and immediately on
disembarkation. The phlebotomists were instructed not to make
m o re than two attempts at venepuncture in an attempt to ensure
volunteer compliance and not impact negatively on future
volunteer re c ruitment. Blood was taken from each volunteer
passenger using a 21-gauge needle and the Becton Dickinson
Vacutainer system. Pre- and post-flight blood samples collected
included one 5 ml ethylenediamine tetra-acetic acid (EDTA),
one 10 ml serum separation table (SST) and two 5 ml sodium
citrate standard Becton Dickenson Vacutainer tubes.
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Specimen preparation
The blood specimens collected in 0.105M (3.2%) trisodium
citrate (9 volumes blood: 1 volume citrate) tubes were
centrifuged at 2 500 g for 10 minutes. Specimens collected pre-
flight at Heathrow Airport were centrifuged, plasma separated,
aliquoted into plastic tubes and frozen at –20°C within 30
minutes of collection. The pre-flight specimens were
transferred from Heathrow Airport to St Thomas’s Hospital,
London, each evening for storage at –20°C for 1 month and
subsequently at –70°C. On completion of the study all plasma
specimens were couriered on dry ice to the National Health
Laboratory Service Laboratories at Johannesburg Hospital
(South Africa) for testing. The post-flight specimens were
transferred from the Johannesburg International Airport to the
Johannesburg Hospital Laboratories for processing after the
arrival of each flight. The maximum time between blood
collection and processing and/or freezing was 3 hours. The
buffy coat was separated from the EDTA specimen post platelet
count analysis and stored at –70°C until DNAextraction was
performed for factor V Leiden and prothrombin 20210Agene
mutation analysis.
Specimen analysis
All specimens were analysed by the National Health
Laboratory Service. The post-flight EDTA specimens
underwent platelet count analysis on a Coulter GENS within 4
hours of collection. The pre-flight trisodium citrate specimens
underwent D-dimer testing. Analysis of the post-flight
trisodium citrate specimens included assays for D-dimers,
fibrinogen, factor VIII (FVIII), protein C (PC), protein S (PS)
and antithrombin (AT). Anticardiolipin testing was performed
on blood collected in the SST tubes.
The international normalised ratio (INR), activated partial
thromboplastin time (aPTT) and D-dimer analyses were
performed on an Automated Coagulation Laboratory (ACL)
Futura (Instrumentation Laboratories, Milan) using
Thromborel R (Dade Behring — ISI 1.01), ILaPTT SPliquid
reagent (Instrumentation Laboratories) and ILD-dimer kit
(Instrumentation Laboratories) reagents respectively. The latter
kit has been validated in our laboratory against the Gold D-
dimer enzyme-linked immunosorbent (ELISA) assay. Any
value ³  500 ng/ml was considered positive.
The FVIII, fibrinogen, PC and AT were analysed on an ACL
9000 (Instrumentation Laboratories). The FVIII was assayed
using FVIII-deficient plasma from Dade Behring and ILaPTT
SP reagent. The control plasma used was standard human
plasma (SHP) from Dade Behring. The fibrinogen, PC and AT
tests were all performed using standard Instrumentation
Laboratories reagents. The PS testing was performed on an
ACL3000 using the Instrumentation Laboratories Functional
Protein S kit. The anticardiolipins were assayed with the
QACAimmunoglobulin G (IgG) and immunoglobulin M (IgM)
ELISAkits from Cheshire Diagnostics Limited.
Factor V Leiden and prothrombin mutations were analysed
using a multiplex assay and real-time PCR. Genomic DNAwas
extracted from peripheral blood anticoagulated with EDTA
using the method previously described.12 The multiplex PCR
used contained two unlabelled primer sets and two pairs of
fluorescent labelled probes. A 306-bp fragment of the Factor V
gene was amplified using unlabelled primers and labelled
probes previously reported.13 A 291-bp fragment of the
prothrombin gene was also amplified using unlabelled primers
and labelled probes previously described.14 PCR reactions were
performed using the LightCycler. Fluorescence was measured
continuously during the melting curve analysis.
Lower limb CUS
After venepuncture had been carried out at Johannesbur g
International Airport, passengers were asked to stay for CUS of
the deep venous system of both legs. The paired venae
commitantes of the calf, the soleal, popliteal and the femoral
veins were all insonated. This was done by five experienced
ultrasound technicians (employees of Tecmed South Africa
under Toshiba Japan) using Toshiba Nemio 20 ultrasound
machines with 7211 MHz probes.
Passengers without connecting flights who were unwilling to
wait were asked to attend the Milpark Hospital for an
ultrasound assessment within 1 week of disembarkation. A
single senior ultrasonographer performed these delayed
ultrasounds using a Hewlett Packard instrument with a 7210
MHz probe.
A second senior ultrasonographer and a vascular surgeon
randomly checked all ultrasound examinations. The same
vascular surgeon reviewed all the ultrasound films of those
passengers who were shown to have positive D-dimers.
Follow-up
Attempts were made to contact all passengers who supplied
telephone contact details 6 months after this study flight in
order to ascertain whether there were any clinical sequelae
suggestive of VTE because of the flight studied.
Statistical analysis
A logistical regression analysis was performed using Stata
version 7 statistical software to assess risk factors that
contributed to a positive D-dimer result ( ³  500 ng/ml). Only
subjects with complete datasets were included in the analysis.
In the logistical regression analysis D-dimer positivity was
initially regressed against all the characteristics in Tables Iand
II, after which those characteristics with high p-values and
odds ratios (ORs) close to 1 were removed. In the final analysis
class travelled, presence of factor V Leiden mutation, FVIII
levels, aspirin use, age, sex, height in 10 cm units, weight in 10
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kg units and smoking status were regressed against D-dimer
positivity for 778 passengers who had complete data.
Ethics approval
The study was approved by the Ethics Committees for Human




These are summarised in Tables I and III. Business class and
first class passengers were analysed together as the majority of
passengers who flew in business class had a flat bed. There was a
4:1 ratio of economy class to business class passengers re c ru i t e d
despite an attempt to obtain equivalent numbers. There was a
similar number of men and women in the economy class gro u p
but a 2:1 ratio of men to women in business class. While the height,
weight and fluid intake were similar in both classes, the mean
alcohol intake was 66% higher in business class. Only 6% of all
passengers in both classes exercised during the flight.
D-dimers
Nine of the 491 samples taken at departure from Heathrow had
D-dimer levels higher than 500 ng/ml, 1% from business class
and 2% from economy class (Table III). These 9 passengers
were excluded from further analysis. Seventy-four of 899
samples taken on arrival had elevated D-dimers (Table III).
Twenty-two of 180 business class passengers had elevated
levels compared with 52/719 in economy class (7%). This
difference was not significant (OR 0.61, p = 0.109).
Logistical regression analysis on 784 passengers with
complete datasets produced significant positive correlations
between elevated D-dimers and the presence of the factor V
Leiden mutation (OR 3.36, p = 0.024), FVIII levels (OR 1.01, 
p = 0.014) and the use of aspirin (OR 2.04, p = 0.038) (Table IV).
A separate logistical regression analysis on D-dimers was
performed on the subset of female passengers who were taking
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Table I. Passenger demographic data
Characteristics Business class Economy class
Number 180 719
Age
Median (years) 47 43




Median height (cm) 176 173
Range (cm) 130 - 201 120 - 210
Median weight (kg) 82 76
Range (kg) 49 - 126 44 - 168
Median fluid intake (l) 1.0 1.0
Range (l) 0 - 3.25 0- 5.00
Mean alcohol intake (l) 0.250 0.175
Range (l) 0 - 2.38 0 - 1.5
Exercise (yes/no) 10/170 41/678
Percentage (yes) 6 6
Smokers (yes/no) 25/155 121/598
Percentage (yes) 14 17
Passengers (N (%))
Using aspirin 22 (12.2) 89 (12.4)
Using anti-inflammatories 4 (2.2) 26 (3.6)
Using sleeping tablets 24 (13.3) 94 (13.1)
Using OCs 9 (5) 72 (10)
Using HRT 12 (6.7) 71 (9.9)
Ultrasound (N %))
Immediate 77 (42.8) 310 (43.1)
Within 7 days 9 (5) 38 (5.3)
OCs = oral contraceptives; HRT = hormone replacement therapy.




Test tested deficient results
Factor V Leiden 844 31 3.7
Prothrombin 20210A 844 22 2.6
Protein C (IU/dl) 873 18 2
(normal range 70 - 160)
Antithrombin (IU/dl) 873 5 0.6
(normal range 76 - 125)
Protein S (IU/dl) 871 79 9
(normal range 60 - 140)
ACLAIgG GPLU/ml 817 9 1.1
(normal range < 16)
ACLAIgM MPLU/ml 817 12 1.5
(Normal range < 14)
Number
Test of tests Mean Range
Factor VIII (%) 899 107.5 33 - 293
(normal range 50 - 150)
Fibrinogen (g/l) 873 2.94 0.66 - 6.58
(normal range 2 - 4)
Platelet count (x 10 9/l) 702 271 127 - 497
(normal range 140 - 400)
Table III. D-dimer results per class
Business class Economy class
passengers passengers
D-dimers > 500 ng/ml 22/180 (12) 52/719 (7)
on disembarking (N (%))
D-dimers > 500 ng/ml 1/104 (1) 8/387 (2)
on embarking (N (%))
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HRT or OCs (Table V). There were 382 female passengers with
complete datasets available for this assessment. The OR of 2.15
for HRT might be clinically significant even though the p-value
is 0.083.
Lower limb CUS
Three hundred and eighty-seven passengers had CUS on
arrival and 47 passengers had it performed 1 week after
arrival. None of the 434 passengers who were assessed had
evidence of venous thrombosis of the lower limbs. Two
passengers had equivocal scans on arrival. Their femoral veins
were compressible but appeared to have diminished flow. Both
of these passengers had repeat examinations within 2 days,
which were normal, and both had D-dimers within the normal
range.
Follow-up
Telephonic contact details were available for 627 of the 899
passengers, of whom we were able to contact 505 (81%) within
6 months of the study flight. Sixty-four of 74 passengers with
positive post-flight D-dimers were contacted. None of the
passengers contacted reported any signs or symptoms of a
delayed thrombotic event pertaining to the study flight. One
passenger reported that he developed a clinical deep-vein
thrombosis (DVT) after a long flight that he had made six
flights after the study flight.
Discussion
There is considerable anecdotal evidence that DVT can follow
prolonged airline flight and other forms of travel. This has
been reinforced by more recent trials and surveys. 2-6,15 Two
studies have suggested a high prevalence of the condition in
high-risk passengers,3,5 although cockpit crew do not appear to
be affected.16 There is, however, no evidence that the economy
class syndrome exists, although it is now part of popular
mythology.
Our study specifically excluded passengers with a history of
VTE, recent surgery, and current pregnancy. No passenger used
compression stockings. The study therefore focused on
passengers at low or intermediate risk of developing
thrombosis. This is the first study that has specifically
examined the association between markers of thrombosis (D-
dimer) and class of travel.
In contrast to what we expected, there was no statistical
relationship between flight class and the development of
elevated D-dimers. We had hoped for a more even distribution
between the number of business and economy class
passengers, but volunteers in economy class outnumbered
those in business class. This discrepancy was probably caused
by a limited number of business class seats per flight and the
fact that many of the business class passengers either checked
in late or did not wish to be delayed on disembarking. The
similarity in the percentage of passengers with raised D-dimers
in both classes might have been the result of immobility rather
than the cramped seating as only 6% of passengers reported
exercising during the flight.
Although fewer pre-flight D-dimer assays were performed
compared with post-flight specimens due to an entire batch of
specimens becoming activated during transportation and being
discarded, over 7% of our passengers developed raised D-
dimers post-flight. This contrasts with the study by Scurr et al.3
where no D-dimer elevation was found, perhaps because blood
collection was delayed. The NZATT study17 has also recently
reported elevated D-dimers in passengers following long-haul
flights.
In contrast to previous reports none of the passengers in this
study who agreed to be examined had ultrasonic evidence of
lower limb thrombosis.3,5,17 Unfortunately many of the
passengers declined CUS examination at the end of their long
flight. Only 47% of business class and 48% of the economy
class passengers agreed to be examined and only 51% of the
passengers who had positive D-dimers had ultrasound scans
performed. Although the overall percentage of passengers who
underwent lower limb CUS was low, there was no bias
between the positive and negative D-dimer subgroups. The
majority of the ultrasound scans were performed on arrival
and this may have resulted in developing thrombi being
missed. However, none of the 47 late ultrasounds showed
evidence of thrombi. Furthermore, approximately 90% of
passengers with elevated D-dimers were contacted at 6 months
and none reported any symptoms suggestive of VTE.
The sensitivity of CUS for the detection of thrombi in the
lower limb is excellent above the knee, but its utility in the
Table IV. Regression analysis of factors that have a statistically
significant association with positive D-dimers in both sexes
95% confidence
Odds ratio P-value interval
Factor V Leiden 3.36 0.024 1.17 - 9.63
Factor VIII 1.01 0.014 1.00 - 1.01
Aspirin 2.04 0.038 1.04 - 3.99
Table V. Regression analysis of potential hormonal factors
contributing to the development of positive D-dimers in females
95%
confidence
Odds ratio P-value interval
Hormone replacement 2.15 0.083 0.91 - 5.10
therapy
Oral contraceptive 1.23 0.707 0.42 - 3.62
ORIGINAL ARTICLES
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detection of calf vein thrombi is far less impressive.9 In
contrast, D-dimer measurement is a highly sensitive test but
lacks specificity.18 The clinical significance of elevated D-dimers
is difficult to assess. Studies have shown that the D-dimer test
is a useful first-step investigation in patients with clinical signs
and symptoms suggestive of DVT or pulmonary embolism.10,18,19
The very high negative predictive value has led to the adoption
of this strategy in clinical practice, principally to minimise
unnecessary patient exposure to radiological investigations,
which are both costly and not without morbidity. It is
particularly useful in assessing non-surgical patients as
positive D-dimers are almost always observed postoperatively.
The D-dimer is an end product of plasmin digestion of cross-
linked fibrin, which in turn is generated by thrombin.20 The D-
dimer is therefore a marker of thrombin generation signifying
that the coagulation cascade must have been triggered. The
level of elevation of D-dimers is dependent on the mass and
age of the thrombus and hence D-dimers may be raised
without radiological evidence of thrombosis at the time of
testing in patients presenting with symptoms suggestive of
thrombosis.18,21 Bernardi et al.21 confirmed this concept in their
study in which 6% of subjects with positive D-dimers at
presentation subsequently developed DVTs despite an initial
normal ultrasound study.
It must be accepted that the D-dimer is at best a surrogate
marker of thrombosis and may be elevated in the absence of
thrombus. It is interesting, however, that factor V Leiden (the
major inherited risk factor for venous thrombosis) was
identified as an independent risk factor in passengers with
elevated D-dimers. The incidence of 3.7% heterozygous
individuals in this study is comparable with general
population studies in the Western world.22 The question of
whether pre-flight knowledge of factor V Leiden genotype
would influence the implementation of in-flight prophylaxis
requires a prospective study.
The prothrombin gene 20210Amutation was identified in
2.6% of passengers but surprisingly was not a predictor of
positive D-dimers. The other routine tests of hereditary
thrombophilic states, i.e. protein C, protein S and antithrombin
deficiencies, likewise did not prove to contribute to positive D-
dimers. The number of passengers with low protein S levels
was surprisingly high and did not correlate with the use of
oestrogen products. The presence of anticardiolipin antibodies
was not related to positive D-dimers. Although statistically
significant, it is difficult to draw any definite conclusion from
the finding of the correlation between elevated factor VIII
levels and positive D-dimers in the absence of an elevated odds
ratio (OR 1.01). The very tight 95% confidence interval (1.00 -
1.01) is, however, intriguing. Factor VIII becomes elevated
during stress and the stress of flying possibly contributes to an
underlying thrombophilic state. However, an elevated factor
VIII level consequent to subclinical thrombosis as suggested by
positive D-dimers cannot be excluded.
There was a relationship between HRT and elevated D-
dimers. This observation, although not statistically significant,
suggests that women using this medication should be
particularly cautious when travelling long distances. Positive
D-dimers were, however, not correlated with OC usage. In
light of the well-documented association between OC usage
and VTE, this observation cannot be explained.23,24 In particular
there was no association with age.
Smoking status was not related to the development of
positive D-dimers. Smoking is a potent cause of arterial
thrombosis but there is not much evidence linking it to venous
thrombosis. Although one might have expected that passengers
who were taller or heavier than the norm, and therefore subject
to greater in-flight space restriction, would have a higher
incidence of elevated D-dimers, this was not borne out by the
statistical analysis.
An assessment of advice previously offered to passengers,
viz. to increase fluid intake, limit alcohol intake and actively
perform the exercises recommended in the in-flight magazine,
revealed that none of them could be supported by the results of
our study. The use of sleeping tablets was expected to be a
potential factor contributing to the tendency to thrombosis by
decreasing in-flight movement. No association was noted.
Aspirin, but not other anti-inflammatory agent usage, was
statistically significantly associated with positive D-dimers.
Aspirin has been well documented to prevent arterial
thrombosis but the evidence for its preventing venous
thrombosis is far less convincing.25,26 It is unlikely that it causes
thrombosis. A more plausible theory is either that it caused
gastritis, which falsely elevated the D-dimers, or that the
passengers who used aspirin comprised a group of high-risk
individuals. The NZATT study17 has now reported that aspirin
does not prevent travel-associated venous thromboses.
In conclusion, in the largest prospective study to date, we
have shown that the incidence of clinical and/or CUS-
documented lower limb venous thrombosis is much lower than
has been previously reported as it occuured in none of the
passengers studied. No passenger reported symptoms of DVT
or pulmonary embolism within 6 months of the study flight.
This may in part be explained by differences in passenger
demographics as high-risk passengers were excluded from this
study. We  have also demonstrated that a significant number of
passengers developed elevated D-dimer levels during flight.
This was unrelated to flight class. The large prospective study
proposed by the WHO may shed further light on the true risk
of air travel-associated thrombosis.
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